Ku­ra’s stock jumps on PhIb read­out; FDA lifts hold on IN­mune Bio pro­gram; Nanobi­otix’s $20M mile­stone

Plus, news about Iterum Ther­a­peu­tics, As­tria Ther­a­peu­tics, Aqemia, Ake­bia Ther­a­peu­tics, Tour­ma­line Bio and Ve­ra Ther­a­peu­tics:

Ku­ra On­col­o­gy’s pos­i­tive PhIb read­out: The com­pa­ny

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER